NCT01529944

Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.

Conditions

• Genetic Disorder
• Noonan Syndrome

Interventions

Type	Name	Description
DRUG	somatropin	Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
DRUG	somatropin	Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2012-02-09
• Last updated: 2023-08-09

Locations

1 site across 1 country: Sweden